Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

What You'll Want to Know About Inovio Pharmaceuticals' Q1 Earnings Update

By Keith Speights - May 10, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

More revenue, more cash, lower expenses, and a lot of pipeline activity were the major stories for the biotech in Q1.

The numbers didn't look very good for Inovio Pharmaceuticals Inc. ( INO -7.26% ) when it announced its fourth-quarter results in March. Revenue fell by 28% year over year while its net loss worsened. But that's par for the course for a clinical-stage biotech.

The company announced its first-quarter results after the market closed on Thursday. Here are the highlights from Inovio's Q1 update.

Two people in lab coats taking notes and holding test tubes.

Image source: Getty Images.

By the numbers

Inovio's top-line performance improved in the first quarter. Revenue jumped to nearly 87% year over year to $2.8 million. Analysts estimated that the company's revenue for the first quarter would come in at $6.41 million.

The company reported a first-quarter net loss of $29.2 million, or $0.30 per share, on a GAAP basis, compared to a net loss of $32.4 million, or $0.36 per share, in the same period in 2018. Wall Street analysts were expecting a Q1 net loss of $0.26 per share.

Inovio ended the first quarter with cash, cash equivalents, and short-term investments of $128 million. This was an increase from the $81.2 million on hand as of March 31, 2019.

Behind the numbers

Inovio doesn't have any products on the market yet. All of its revenue comes from collaborations and grants. The company's revenue increase in the first quarter was due mainly to a milestone payment received as part of its collaboration with big pharma company AstraZeneca.

Inovio's bottom line improved in the first quarter compared to the prior-year period in large part because of the higher revenue. The company also cut costs -- total operating expenses fell 8.5% year over year to $31.4 million. The biggest contributor to this decrease was lower general and administrative expenses.

Other highlights from the company's first-quarter update include:

  • Inovio's experimental drug VGX-3100 was granted an Advanced Therapy Medicinal Product certificate by the European Medicines Agency's (EMA) committee.
  • VGX-3100 was selected in April as the 2019 "Best Therapeutic Vaccine" at the World Vaccine Congress.
  • Completed enrollment of the phase 1/2 study evaluating INO-5401 in treating patients with newly diagnosed glioblastoma (GBM).
  • Presented preclinical results for the company's DNA-encoded bi-specific T cell engagers (dBiTEs) technology at the American Association for Cancer Research (AACR) meeting.
  • Dosed the first patient in the initial clinical study evaluating the company's DNA-encoded monoclonal antibody (dMAb) technology in treating the Zika virus.
  • Former Merck Vaccines executive Simon Benito was appointed chairman of Inovio's board of directors.

Looking ahead

Inovio should soon complete full enrollment for its Reveal 1 phase 3 study of VGX-3100 in treating cervical dysplasia caused by human papillomavirus (HPV). The company also anticipates reporting interim data from the two phase 2 studies of VGX-3100 in treating patients with vulvar and anal dysplasia later in 2019.

There should be more news for INO-5401 on the way as well. Inovio anticipates reporting interim results from its phase 1/2 study of INO-5401 in combination with Regeneron's Libtayo before the end of this year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$6.13 (-7.26%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.